The LucidQuest Ecosystem
Consulting and specialist tools for biopharma, digital health and investors: see what is changing, find and validate the evidence, and test decisions before the market does.
LucidQuest is a global strategy and competitive insights firm for biopharma, digital health and investors, based in London. We help teams uncover threats, seize opportunities and make strategic decisions with confidence, through primary research, congress coverage, competitive strategy, AI-powered wargaming and investment decision support.
You can work with LucidQuest in two ways: through consulting engagements led by our team, or through specialist tools that LucidQuest builds and runs. Many clients combine both. The tools are organised by the job they do: to sense what is changing in your market (NexusBrain, LucidScope, LucidTrends, LucidAlpha), to find and validate the evidence (LucidSearch, QuickAnswers), to pressure-test decisions before the market does (LucidWargames) and to go deeper in a specific therapy modality (LucidCGT).
This page explains what each part of the ecosystem does, who it is for and how it is delivered, so you can choose where to start.
Last updated: 2026-11-01
Which tool for which question
| Your question | Start with |
|---|---|
| We need a competitive intelligence, congress coverage, wargaming or investment diligence programme run by an experienced team. | LucidQuest consulting |
| What are our own field teams seeing at congresses, launches and customer meetings? | NexusBrain |
| What do ChatGPT, Gemini, Claude and Perplexity say about our brand and our competitors? | LucidScope |
| What are patients and healthcare professionals searching for, where, and is interest rising or falling? | LucidTrends |
| Is a drug candidate's momentum building or fading, and which events drove the change? | LucidAlpha |
| Where can I quickly find biopharma-specific analyst, clinical, patent and podcast sources? | LucidSearch |
| What do KOLs, physicians and payers think, and can we find out quickly? | QuickAnswers |
| How will competitors respond if we make this move, and which option holds up? | LucidWargames |
| What is the competitive and commercial outlook for our cell, gene or RNA therapy? | LucidCGT |
LucidQuest consulting: strategy and intelligence led by our team
LucidQuest's team delivers pharmaceutical competitive intelligence from development through commercialisation, combining in-house expertise with a specialist network across oncology and haematology, rare diseases, immunology, neuroscience, respiratory, cardiovascular and metabolic diseases, infectious diseases and vaccines. Engagements use the tools below wherever they help, and can be captured in NexusBrain so that every project adds to a lasting intelligence asset.
- Competitive intelligence across therapy areas: landscapes, competitor tracking and strategy from pipeline assets to mature brands
- Conference coverage: previews, real-time tracking and strategic debriefs for major congresses such as ASCO, ESMO, ASH, AHA and JPM
- Primary intelligence: KOL, payer, patient and stakeholder research, including rapid QuickAnswers
- Wargames and workshops: AI-powered wargames with LucidWargames, plus traditional facilitated workshops
- Investor diligence and decision support: independent diligence and decision support for investment teams, including Lucid Diligence Briefs on recent deals and partnerships
- Specialist practices: digital health and AI; gene and cell therapy and rare diseases; vaccines and infectious diseases
- Monthly strategic roundups: what changed each month in key therapy areas
- Best for: We need a competitive intelligence, congress coverage, wargaming or investment diligence programme run by an experienced team.
- Who it is for: Biopharma and healthtech leaders, and investors.
- How it is delivered: Consulting engagements and facilitated workshops
- Links: info@lqventures.com · lqventures.com
Sense: See what is changing in your market
NexusBrain
NexusBrain captures, structures and activates the intelligence your own people gather: field observations, congress notes, primary research findings and wargame outputs. Instead of living in static reports and slide decks, it becomes a searchable, cumulative and expert-validated asset that also gives your AI tools better inputs.
- Best for: What are our own field teams seeing at congresses, launches and customer meetings?
- Who it is for: Organisations that want their teams' field and congress insight to build up over time.
- How it is delivered: Software platform
- Links: NexusBrain website
LucidScope
LucidScope monitors how ChatGPT, Gemini, Claude, Perplexity and other AI assistants describe your company, therapies and competitors. It maps perception and answers across models, markets and stakeholder lenses (patient, HCP and payer), traces the sources shaping those answers, and flags risks such as hallucinations and outdated claims. LucidQuest publishes regular LucidScope AI visibility audits by therapy area.
- Best for: What do ChatGPT, Gemini, Claude and Perplexity say about our brand and our competitors?
- Who it is for: Commercial, digital, medical, safety and market access teams in pharma and healthcare.
- How it is delivered: Software platform and AI answer audits
- Links: LucidScope website · LucidScope at LucidQuest · LucidScope AI audit analyses
LucidTrends
LucidTrends turns multi-country, multi-keyword search-interest data into early signals on demand, competitors and market gaps. It combines geo heatmaps, trend tracking and forecasting, and related-query analysis that reveals treatment-journey questions and emerging demand, with unlimited keywords, any market and custom timeframes.
- Best for: What are patients and healthcare professionals searching for, where, and is interest rising or falling?
- Who it is for: Brand and marketing, competitive intelligence, portfolio and new-product planning, and market research teams.
- How it is delivered: Software platform with on-demand dashboards
- Links: LucidTrends website
LucidAlpha
LucidAlpha turns biotech and pharmaceutical events into a quantitative signal, like a stock chart for drug development. Each drug candidate gets a 0–100 composite score built from events in eight categories, from clinical and regulatory to safety, weighted by development stage and fading over time, with sentiment and confidence scoring, technical indicators, Google Trends correlation and scenario modelling.
- Best for: Is a drug candidate's momentum building or fading, and which events drove the change?
- Who it is for: Competitive intelligence teams, portfolio monitors and investment analysts.
- How it is delivered: Software platform
- Links: LucidAlpha website
Understand: Find and validate the evidence
LucidSearch
LucidSearch is a search engine dedicated to biopharma and healthcare. Category tabs such as analyst views, clinical, patents and podcasts narrow results to the sources that matter, and results can be emailed to colleagues.
- Best for: Where can I quickly find biopharma-specific analyst, clinical, patent and podcast sources?
- Who it is for: People in biopharma and healthcare who need focused sources quickly.
- How it is delivered: Web search tool
- Links: LucidSearch at LucidQuest
QuickAnswers
QuickAnswers connects you directly with KOLs, physicians, payers and other market and industry stakeholders for information that is not in public data. It is built for fast questions: validating assumptions, gauging expert sentiment on a data readout or competitive move, or deciding whether a question justifies a deeper study, typically with 5–10 expert perspectives. Findings can be captured in NexusBrain.
- Best for: What do KOLs, physicians and payers think, and can we find out quickly?
- Who it is for: Brand, strategy, medical and business development teams that need expert input on a decision timeline.
- How it is delivered: Primary research service
- Links: QuickAnswers at LucidQuest
Test: Pressure-test decisions before the market does
LucidWargames
LucidWargames is an AI-powered, multi-agent wargaming engine. Teams can play against AI competitors, let autonomous agents play the whole wargame as an unbiased baseline, have AI adjudicate each round against weighted KPIs, and batch many runs with Monte Carlo simulation to map likely outcomes. It is available self-serve, from $490 per wargame, or as a facilitated workshop with your leadership team.
- Best for: How will competitors respond if we make this move, and which option holds up?
- Who it is for: Strategy, commercial and leadership teams in biopharma and healthtech, as well as finance, venture capital, energy and manufacturing.
- How it is delivered: Self-serve platform and facilitated workshops
- Links: LucidWargames website · LucidWargames at LucidQuest · LucidWargames case studies
Specialist: Deep expertise by therapy modality
LucidCGT
LucidCGT is LucidQuest's specialist practice for cell, gene and RNA therapies. It covers competitive intelligence (landscapes, competitor profiles, catalyst tracking, conference intelligence and expert interviews), strategic wargaming with LucidWargames, investment and partnering insight, and commercial strategy, through formats such as the CGT Conference & Landscape Sprint, the CGT Strategy Stress Test and the CGT Intelligence Partner.
- Best for: What is the competitive and commercial outlook for our cell, gene or RNA therapy?
- Who it is for: Emerging biotechs, established biopharma, investors and venture funds, and technology and service firms in advanced therapies.
- How it is delivered: Specialist consulting
- Links: LucidCGT website · Gene & cell therapy consulting at LucidQuest
Working with LucidQuest
Every tool is backed by LucidQuest’s analysts and methodology. Teams can use a tool on its own, or combine several in one engagement: for example, capturing field insight in NexusBrain, spotting a change with LucidScope or LucidTrends, validating it with QuickAnswers, and testing the response with LucidWargames.
Not sure where to start? Contact us at info@lqventures.com.